Iobenguane I-123 - GE Healthcare

Drug Profile

Iobenguane I-123 - GE Healthcare

Alternative Names: 123I-Iobenguane; 123I-mIBG; 3-iodobenzylguanidine I-123; AdreView; Iobenguane I123 Injection; Metaiodobenzylguanidine I-123 - GE Healthcare

Latest Information Update: 11 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GE Healthcare
  • Developer GE Healthcare; University of Ottawa Heart Institute
  • Class Antineoplastics; Iodobenzenes; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Neuroendocrine tumours
  • Registered Neuroblastoma

Most Recent Events

  • 11 Apr 2018 GE Healthcare terminates a phase III trial for Heart failure (Diagnosis) in USA, Canada, France, Italy, Netherlands, Poland, Hungary, Spain, Czech Republic, Germany and Denmark due to lower rate of recruitment of patients (NCT02656329)
  • 01 Jan 2016 GE Healthcare initiates enrolment in a phase-III trial for Heart failure (Diagnosis) in USA (IV) (NCT02656329)
  • 01 Dec 2013 Phase-III clinical trials for Heart failure (Diagnosis) in Canada (IV) (NCT02043522)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top